Drugs. ;68(12) Fentanyl transdermal matrix patch (Durotep MT patch; Durogesic DTrans; Durogesic SMAT): in adults with cancer-related pain. Indications, side effects, contraindications and other prescribing information for Durogesic DTrans on MIMS. Following an abbreviated submission. transdermal fentanyl (Durogesic D Trans patches) 12 mcg/hour is accepted for restricted use within NHS.

Author: Faedal Meztisar
Country: Mauritius
Language: English (Spanish)
Genre: Career
Published (Last): 15 May 2004
Pages: 467
PDF File Size: 18.95 Mb
ePub File Size: 20.14 Mb
ISBN: 230-2-90977-691-3
Downloads: 88241
Price: Free* [*Free Regsitration Required]
Uploader: Mikakus

General disorders and administration site conditions. Patients with myasthenia gravis Non-epileptic myo clonic reactions can occur. The dose should be dugagesic individually until a balance between analgesic efficacy and tolerability is attained. Paediatric population The safety of Durogesic DTrans was evaluated in 3 open-label studies in paediatric subjects with chronic pain, aged 2 to 17 years, inclusive.

Cases of serious respiratory d-trand after coadministration of CYP3A4 inhibitors with transdermal fentanyl have been reported, including a fatal case after coadministration with a moderate CYP3A4 inhibitor. The adverse reactions reported with the use of Durogesic DTrans from these clinical studies including the above-mentioned adverse reactions, and from post-marketing experiences are listed below in Table 5.

The safety of Durogesic DTrans was evaluated in 3 open-label studies in paediatric subjects with chronic pain, aged 2 to 17 years, inclusive. The safety of Durogesic DTrans was evaluated in 1, adult and paediatric subjects who participated in 11 clinical studies 1 double-blind, placebo-controlled; 7 open-label, active-controlled; 3 open-label, uncontrolled used for the management of chronic malignant or non-malignant pain.

Adequate body temperature and fluid intake should be maintained.

transdermal fentanyl (Durogesic D Trans 12mcg/hr)

This effect could either be due to altered maternal care or a direct effect of fentanyl on the pups. Soaps, oils, lotions, or any other agent that might irritate the skin dufagesic alter its characteristics should not be used.

There are no adequate data from the use of Durogesic DTrans in pregnant women. Name of the medicinal product 2.

DRUG ALERT: Durogesic DTrans 25µg/hour transdermal fentanyl patches | News | Pharmaceutical Journal

Further open the sachet along both sides, folding the sachet open like a book. The treatment of cancer pain. Opioid withdrawal symptoms such as nausea, vomiting, diarrhoea, anxiety, and shivering are possible in some patients after conversion from their previous opioid analgesic to Durogesic DTrans or if therapy is stopped suddenly see section 4.


In such patients, opioids may decrease respiratory drive and increase airway resistance. Thank you for your feedback. Find out more here. After an increase in dose, it may take up to 6 days for the patient to reach equilibrium on the new dose level. Reversal d-tarns the narcotic effect may result in acute onset of pain and release of catecholamines.

If the patch needs to be replaced e. This medicine diragesic impair cognitive function and can affect a patient’s ability to drive safely. Oral doses are those recommended when changing from a parenteral to an oral route. Following Durogesic DTrans application, the skin under the system absorbs fentanyl, and a depot of fentanyl concentrates in the upper skin layers.

duraagesic Accidental exposure by patch transfer Accidental transfer of a fentanyl patch to the skin of a non-patch wearer particularly a childwhile sharing a bed or being in close physical contact with a patch wearer, may result in an opioid overdose for the non-patch wearer.

Fatigue, Oedema peripheral, Asthenia, Malaise, Feeling cold. To bookmark a medicine you must dkragesic up and log in. For more information please take a look at our terms and conditions. Five pouches are assembled in cardboard cartons.

Durogesic D Trans Transdermal Patch. Hypotension Opioids may cause hypotension, especially in patients with acute hypovolaemia. Its primary therapeutic actions are analgesia and sedation.

Tables 1, 2, and 3 should only be furagesic to convert from other opioids to Durogesic DTrans and not from Durogesic DTrans to other therapies to avoid overestimating the new analgesic dose and potentially causing overdose. Tolerance, d-trzns dependence, and psychological dependence may develop upon repeated administration of opioids.

An increase in skin temperature through the application of a heating pad on low setting over the Durogesic DTrans system during the first 10 hours of a single application increased the mean fentanyl AUC value by 2.

Durogesic DTrans 12 mcg/hr Transdermal Patch

Qualitative and quantitative composition 3. Fentanyl concentrations were measured in more than children aged 2 to 17 years who diragesic applied fentanyl patches in the dose range of These subjects received at least one dose of Durogesic DTrans and provided safety data.

  GSW 2401 PDF

In addition, the drug may be used to prevent or relieve tachypnea and postoperative emergence delirium.

The appropriate initiating dose of Durogesic DTrans should be based on the patient’s current opioid use. The barcode on the packaging is also different, and will not be recognised by UK barcode readers. Enter medicine d-frans or company Start typing to retrieve search suggestions. Generally, a patient duagesic wait for 2 days after stopping treatment with a CYP3A4 inhibitor before applying the first Durogesic DTrans patch. Some parts of the site may not work properly if you choose not to accept cookies.

If patients with renal impairment receive Durogesic DTrans, they should be observed carefully for signs of fentanyl toxicity and the dose reduced if d–trans. If the site of Durogesic DTrans application requires cleansing prior to application of the patch, this should be done with clear water. Home Health and social care Medicines, medical devices and blood regulation and safety Vigilance, safety alerts and guidance Alerts and recalls.

Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist.

DRUG ALERT: Durogesic DTrans 25µg/hour transdermal fentanyl patches

The Medicines and Healthcare Products Regulatory Agency recommends that the UK patient information leaflet be downloaded from the electronic medicines compendium website and enclosed with dispensed packs. Respiratory, thoracic and mediastinal disorders. To derive the Durogesic DTrans dosage corresponding to the calculated hour, equianalgesic morphine dosage, use dosage-conversion Table 2 or 3 as follows:.

PIL of the month: It also crosses the placenta and is excreted in breast milk. A patient who is treated with Durogesic DTrans should wait at least 1 week after removal of the last patch before initiating treatment with a CYP3A4 inhibitor.